Viatris Management

Management criteria checks 1/4

Viatris' CEO is Scott Smith, appointed in Apr 2023, has a tenure of 1.5 years. total yearly compensation is $16.27M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 0.007% of the company’s shares, worth €901.13K. The average tenure of the management team and the board of directors is 1.2 years and 4.3 years respectively.

Key information

Scott Smith

Chief executive officer

US$16.3m

Total compensation

CEO salary percentage	6.3%
CEO tenure	1.5yrs
CEO ownership	0.007%
Management average tenure	1.2yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Smith's remuneration changed compared to Viatris's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$646m
Mar 31 2024	n/a	n/a	-US$56m
Dec 31 2023	US$16m	US$1m	US$55m

Compensation vs Market: Scott's total compensation ($USD16.27M) is above average for companies of similar size in the German market ($USD5.11M).

Compensation vs Earnings: Insufficient data to compare Scott's compensation with company performance.

CEO

Scott Smith (62 yo)

1.5yrs

Tenure

US$16,271,094

Compensation

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Smith	CEO & Director	1.5yrs	US$16.27m	0.0072% $ 901.1k
Brian Roman	Chief Legal Officer	7.3yrs	US$4.11m	0.0057% $ 714.6k
Theodora Mistras	Chief Financial Officer	less than a year	no data	no data
Paul Campbell	Chief Accounting Officer	9.4yrs	no data	0.013% $ 1.6m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	no data	no data
Andrew Enrietti	Chief People Officer	3.8yrs	no data	no data
Menassie Taddese	President of Emerging Markets	no data	no data	no data
Derek Glover	Chief Quality Officer	no data	no data	no data
Lara Ramsburg	Chief Corporate Affairs Officer	no data	no data	no data
Jeffrey Nau	President of Viatris Eye Care Division	no data	no data	no data
Philippe Martin	Chief R&D Officer	less than a year	no data	no data
Corinne Le Goff	Chief Commercial Officer	less than a year	no data	no data

1.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: VIA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Smith	CEO & Director	1.8yrs	US$16.27m	0.0072% $ 901.1k
JoEllen Dillon	Independent Non-Executive Director	10.5yrs	US$200.00k	0.0049% $ 620.1k
Wyllie Cornwell	Independent Director	3.9yrs	US$170.00k	0.0051% $ 647.8k
Elisha Finney	Independent Director	1.8yrs	US$170.00k	0.0016% $ 199.1k
James Kilts	Independent Director	3.9yrs	US$170.00k	0.0098% $ 1.2m
Harry Korman	Independent Non-Executive Director	6.3yrs	US$175.00k	0.0075% $ 947.8k
Melina Higgins	Independent Non-Executive Chairman	11.7yrs	US$254.38k	0.015% $ 1.9m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$41.50m	0.053% $ 6.7m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	15.1yrs	US$250.00k	0.010% $ 1.3m
Rajiv Malik	Director	12.8yrs	US$12.48m	0.042% $ 5.3m
Richard Mark	Independent Non-Executive Director	4.8yrs	US$220.00k	0.0061% $ 763.8k
Leo Groothuis	Independent Director	1.4yrs	US$113.54k	0.0019% $ 234.4k

4.3yrs

Average Tenure

63yo

Average Age

Experienced Board: VIA's board of directors are considered experienced (4.3 years average tenure).

Viatris Management

Management criteria checks 1/4

Key information

Recent management updates

Director recently sold €2.1m worth of stock

Director recently sold €3.1m worth of stock

Director recently sold €3.4m worth of stock

Chief Legal Officer recently sold €854k worth of stock

President of Developed Markets recently sold €2.8m worth of stock

Viatris Announces CFO Changes

Recent updates

Viatris Launches (Pr) Viagra ODF in Canada

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold €2.1m worth of stock

Director recently sold €3.1m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Second quarter dividend of US$0.12 announced

Second quarter 2024 earnings released: US$0.27 loss per share (vs US$0.22 profit in 2Q 2023)

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold €3.4m worth of stock

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Chief Legal Officer recently sold €854k worth of stock

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings released: EPS: US$0.095 (vs US$0.19 in 1Q 2023)

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

President of Developed Markets recently sold €2.8m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

Fourth quarter dividend of US$0.12 announced

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Full year 2023 earnings released: EPS: US$0.046 (vs US$1.72 in FY 2022)

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.29 in 3Q 2022)

Viatris Inc., Annual General Meeting, Dec 15, 2023

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Now 23% undervalued

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Viatris Inc. Reaffirms Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.22 (vs US$0.26 in 2Q 2022)

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.33 in 1Q 2022)

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

Full year 2022 earnings released: EPS: US$1.72 (vs US$1.05 loss in FY 2021)

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.26 in 3Q 2021)

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Independent Non-Executive Director recently sold €98k worth of stock

Upcoming dividend of US$0.12 per share

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.23 loss in 2Q 2021)

Viatris Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insider recently sold €99k worth of stock

First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.86 loss in 1Q 2021)